
Phase 3 Development Plan for Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia
Newron Pharmaceuticals announced the approval of the pivotal ENIGMA-TRS phase 3 development program evaluating evenamide as an add-on therapy to current antipsychotics, including clozapine, in patients with treatment-resistant schizophrenia (TRS). This …